# Supplementary figures

Table S 1 Initial HCV RNA decline in subjects with varied disease outcomes

| **Subject** | **DPIa** | **HCV RNA levels log10 IUb/mL** | **HCV RNA changec** | **Time point selected** | **Anti-E2 IgG1 (S/N)f** | **Anti-E2 IgG3 (S/N)** | g **nAb activity** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **023\_Ch** | 36 | 7.28 |  |  |  |  |  |
|  | 44 | 7.25 | 0.03 | Peakd | 0 | 0 | Nh |
|  | 60 | 6.91 | 0.34 | Ye | 0 | 3.58 | N |
|  | 74 | 5.6 | 1.31 | Y | 4.34 | 2.9 | **Y** |
|  | 85 | 3.51 | 2.09 | Y | 2.71 | 2.06 | N |
|  | 101 | 2.6 | 0.91 | Y | 3.76 | 0 | N |
|  | 135 | 6.45 | -3.85 |  | 28.6 | 0 | N |
|  | 197 | 6.77 | -0.32 |  | 51.57 | 2.91 | **Y** |
|  | 365 | 5.71 | 1.06 |  | 51.14 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **240\_Ch** | 44 | 4.74 |  |  | 0 | 0 | N |
|  | 57 | 4.93 | -0.19 | Peak | 0 | 0 | N |
|  | 71 | 4.81 | 0.13 | Y | 0 | 1.39 | N |
|  | 85 | 3.78 | 1.02 | Y | 0 | 0 | N |
|  | 99 | 2.7 | 1.09 | Y | 0 | 0 | N |
|  | 113 | 3.69 | -0.99 |  | 0 | 0 | N |
|  | 140 | 3.01 | 0.67 |  | 0 | 0 | N |
|  | 220 | 4.65 | -1.63 |  | 4.27 | 0 | N |
|  | 538 | 4.79 | -0.14 |  | 4.19 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **256\_Ch** | 44 | 7.53 |  | Peak | 0 | 0 | N |
|  | 58 | 7.28 | 0.25 | Y | 0 | 0 | N |
|  | 79 | 5.91 | 1.37 | Y | 0 | 0 | N |
|  | 96 | 4.71 | 1.2 | Y | 0 | 0 | N |
|  | 112 | 1.7 | 3.01 | Y | 0 | 0 | N |
|  | 129 | 2.84 | -1.14 |  | 0 | 0 | N |
|  | 163 | 2.13 | 0.71 |  | 0 | 0 | N |
|  | 287 | 4.17 | -2.04 |  | 0 | 0 | N |
|  | 570 | 2.86 | 1.31 |  | 4.62 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **4059\_Ch** | 30 | 6.57 |  |  | 0 | 0 | N |
|  | 44 | 7.24 | -0.68 |  | 0 | 0 | N |
|  | 58 | 7.42 | -0.18 | Peak | 0 | 0 | N |
|  | 77 | 6.86 | 0.55 | Y | 1.27 | 0 | N |
|  | 93 | 3.77 | 3.09 | Y | 2.26 | 2.73 | N |
|  | 105 | 5.69 | -1.92 |  | 2.33 | 2.84 | N |
|  | 119 | 5.77 | -0.08 |  | 1.93 | 2.24 | N |
|  | 212 | 6.04 | -0.27 |  | 6.09 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **HOK\_Ch** | 30 | 5.87 |  | Peak | 0 | 0 | N |
|  | 73 | 5.24 | 0.62 | Y | 0 | 0 | N |
|  | 80 | 4.65 | 0.6 | Y | 1.35 | 0 | N |
|  | 93 | 5.61 | -0.96 |  | 1.27 | 0 | N |
|  | 108 | 4.4 | 1.21 |  | 1.38 | 0 | N |
|  | 121 | 4.89 | -0.49 |  | 1.5 | 0 | N |
|  | 149 | 5.41 | -0.51 |  | 6.5 | 0 | N |
|  | 233 | 5.54 | -0.14 |  | 11.98 | 0 | N |
|  | 446 | 5.98 | -0.44 |  | 45.54 | 0 | **Y** |
|  | 618 | 5.01 | 0.97 |  | 48.67 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **THD\_Ch** | 16 | 5.37 |  |  | 0 | 0 | N |
|  | 30 | 5.74 | -0.37 | Peak | 0 | 0 | N |
|  | 44 | 5.25 | 0.49 | Y | 0 | 0 | N |
|  | 58 | 3.3 | 1.94 | Y | 0 | 0 | N |
|  | 72 | 5.04 | -1.73 |  | 0 | 1.76 | N |
|  | 85 | 4.79 | 0.24 |  | 0 | 0 | N |
|  | 109 | 5.7 | -0.91 |  | 0 | 1.97 | N |
|  | 198 | 5.83 | -0.13 |  | 1.69 | 2.59 | N |
|  | 394 | 5.77 | 0.06 |  | 49.81 | 3.48 | **Y** |
|  | 583 | 5.35 | 0.42 |  | 51.4 | 3.53 | **Y** |
|  | 690 | 5.26 | 0.09 |  | 51.52 | 3.23 | **Y** |
|  |  |  |  |  |  |  |  |
| **THG\_Ch** | 2 | 5.15 |  | Peak | 0 | 0 | N |
|  | 16 | 5 | 0.15 | Y | 0 | 0 | N |
|  | 30 | 4.9 | 0.1 | Y | 0 | 0 | N |
|  | 44 | 4.53 | 0.37 | Y | 0 | 0 | N |
|  | 58 | 4.3 | 0.23 | Y | 0 | 0 | N |
|  | 71 | 4.31 | -0.01 | Y | 0 | 0 | N |
|  | 95 | 4.45 | -0.14 |  | 0 | 0 | N |
|  | 184 | 5.35 | -0.9 |  | 0 | 0 | N |
|  | 395 | 2.8 | 2.55 |  | 46.16 | 0 | **Y** |
|  | 569 | 4.88 | -2.08 |  | 49.88 | 0 | **Y** |
|  | 704 | 5.16 | -0.28 |  | 48.16 | 0 | **Y** |
|  |  |  |  |  |  |  |  |
| **168\_Cl** | 4 | 7.04 |  |  | 0 | 0 | N |
|  | 16 | 7.1 | -0.06 |  | 0 | 0 | N |
|  | 32 | 7.59 | -0.48 | Peak | 0 | 0 | N |
|  | 44 | 7.36 | 0.23 | Y | 0 | 0 | **Y** |
|  | 58 | 7.1 | 0.26 | Y | 5.44 | 2.05 | **Y** |
|  | 72 | 7.02 | 0.08 | Y | 9.51 | 2.72 | **Y** |
|  | 100 | 4.72 | 2.3 | Y | 5.1 | 1.85 | **Y** |
|  | 184 | 0 |  |  | 1.36 | 0 | N |
|  |  |  |  |  |  |  |  |
| **277\_Cl** | 39 | 6.74 |  |  | 0 | 0 | N |
|  | 63 | 7.09 | -0.36 | Peak | 0 | 0 | N |
|  | 74 | 7.02 | 0.08 | Y | 0 | 1.46 | N |
|  | 95 | 6.54 | 0.48 | Y | 52.04 | 2.95 | **Y** |
|  | 102 | 4.02 | 2.52 | Y | 53.09 | 3.47 | **Y** |
|  | 116 | 4.85 | -0.82 |  | 53.83 | 2.61 | **Y** |
|  | 144 | 2.92 | 1.93 |  | 53.57 | 9.3 | **Y** |
|  | 245 | 0 |  |  | 54.02 | 25.4 | **N** |
|  |  |  |  |  |  |  |  |
| **306\_Cl** | 12 | 7.04 |  |  | 0 | 4.2 | N |
|  | 26 | 7.11 | -0.07 |  | 0 | 3.58 | N |
|  | 36 | 6.76 | 0.35 |  | 0 | 3.31 | N |
|  | 43 | 6.98 | -0.22 | Peak | 0 | 3.32 | N |
|  | 58 | 6.87 | 0.12 | Y | 2.18 | 3.77 | N |
|  | 85 | 3.64 | 3.23 | Y | 2.73 | 3.63 | **Y** |
|  | 888 | 0 |  |  | 0 | 2.29 | N |
|  |  |  |  |  |  |  |  |
| **360\_Cl** | 30 | 6.75 |  | Peak | 0 | 0 | N |
|  | 44 | 6.66 | 0.09 | Y | 0 | 0 | N |
|  | 58 | 4.15 | 2.51 | Y | 1.64 | 1.82 | N |
|  | 71 | 4.2 | -0.05 | Y | 1.54 | 0 | **Y** |
|  | 83 | 3.03 | 1.18 | Y | 0 | 0 | N |
|  | 97 | 1.18 | 1.85 | Y | 2.03 | 0 | **Y** |
|  | 132 | 1.76 | -0.58 |  | 11.29 | 2.49 | **Y** |
|  | 223 | 0 |  |  | 41.66 | 2.19 | **Y** |
|  |  |  |  |  |  |  |  |
| **686\_Cl** | 33 | 6.38 | -6.38 |  | 0 | 0 | N |
|  | 61 | 7.84 | -1.46 | Peak | 0 | 0 | N |
|  | 75 | 6.71 | 1.13 | Y | 1.24 | 2.3 | N |
|  | 89 | 3.36 | 3.35 | Y | 13.33 | 2.89 | N |
|  | 110 | 1.18 | 2.18 | Y | 2.98 | 0 | **Y** |
|  | 117 | 1.18 | 0 | Y | 2.26 | 0 | **Y** |
|  | 514 | 0 |  |  | 0 | 0 |  |
|  | 629 | 0 |  |  | 0 | 0 | **Y** |
|  | 649 | 0 |  |  | 0 | 0 |  |
|  |  |  |  |  |  |  |  |
| **4032\_Cl** | 44 | 5.38 |  | Peak | 0 | 1.51 | N |
|  | 59 | 5.21 | 0.16 | Y | 0 | 1.51 | **Y** |
|  | 72 | 5.07 | 0.14 | Y | 0 | 0 | **Y** |
|  | 86 | 1.18 | 3.9 | Y | 0 | 0 | **Y** |
|  | 100 | 3.47 | -2.29 |  | 0 | 0 | **Y** |
|  | 148 | 0 |  |  | 0 | 1.44 | **Y** |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| **4087\_Cl** | 44 | 7.12 |  |  | 1.27 | 0 | N |
|  | 56 | 7.47 | -0.35 | Peak | 1.47 | 0 | **Y** |
|  | 75 | 6.81 | 0.66 | Y | 13.15 | 4.35 | N |
|  | 84 | 6.29 | 0.52 | Y | 22.58 | 3.75 | **Y** |
|  | 130 | 1.4 | 4.89 | Y | 3.98 | 1.9 | N |
|  | 147 | 0 |  |  | 2.39 | 1.87 | N |
| a Days post-infection, b International Units, c HCV RNA change when compared to previous time point, d Peak HCV RNA time points, e Yes, f Signal to noise, g Neutralising antibody, h No | | | | | | | |